Gina Columbus

Articles

Ipatasertib/Abiraterone Regimen Improves Radiographic PFS in mCRPC With PTEN Loss

June 19th 2020

The combination of ipatasertib plus abiraterone acetate and prednisone/prednisolone improved radiographic progression-free survival compared with standard treatment plus placebo in patients with metastatic castration-resistant prostate cancer who have PTEN loss.

Neoadjuvant Atezolizumab/Chemo Combo Improves pCR in Early TNBC

June 18th 2020

The combination of atezolizumab and nab-paclitaxel, followed by doxorubicin and cyclophosphamide, demonstrated a statistically significant and clinically meaningful improvement in pathological complete response compared with placebo plus chemotherapy as a neoadjuvant treatment for patients with early triple-negative breast cancer, regardless of PD-L1 expression.

Rolling Submission Completed for Umbralisib in Previously Treated MZL and Follicular Lymphoma

June 17th 2020

A new drug application has been completed and submitted to the FDA for the accelerated approval of umbralisib as a treatment for patients with previously treated MZL and follicular lymphoma.

FDA Grants Liposomal Irinotecan Fast Track Status for Frontline Metastatic Pancreatic Cancer

June 17th 2020

The FDA has granted a fast track designation to liposomal irinotecan for use in combination with 5-fluorouracil/leucovorin and oxaliplatin as a treatment for patients with previously untreated, unresectable, locally advanced or metastatic pancreatic ductal adenocarcinoma.

Abemaciclib Significantly Improves iDFS in High-Risk HR+ Early Breast Cancer

June 16th 2020

Abemaciclib in combination with standard adjuvant endocrine therapy demonstrated a significant improvement in invasive disease-free survival compared with endocrine therapy alone in patients with high-risk, HR-positive, HER2-negative early breast cancer.

Plinabulin/Pegfilgrastim Combo Shows Efficacy in Prevention of Severe Neutropenia

June 15th 2020

The combination of plinabulin and pegfilgrastim showed a significant enhancement in the rate of grade 4 neutropenia prevention compared with pegfilgrastim alone in patients undergoing chemotherapy, meeting the primary end point of a prespecified interim analysis of the phase 3 PROTECTIVE-2 trial.

Isatuximab Triplet Significantly Improves PFS in Relapsed/Refractory Myeloma

June 14th 2020

The triplet therapy of isatuximab-irfc, carfilzomib, and dexamethasone showed a statistically significant improvement in PFS versus carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Narsoplimab Significantly Improves Outcomes in HSCT-TMA

June 12th 2020

Treatment with narsoplimab (OMS721) led to complete responses, improved laboratory markers, and encouraging 100-day survival rates in patients diagnosed with hematopoietic stem cell transplant-thrombotic microangiopathy.

Ibrutinib/Venetoclax Triplet Demonstrates Frontline Activity in High-Risk CLL

June 12th 2020

The triplet regimen of ibrutinib, venetoclax, and obinutuzumab demonstrated encouraging response rates with an acceptable safety profile in treatment-naïve patients with high-risk chronic lymphocytic leukemia.

Long After COVID-19, Telemedicine Is Here to Stay in Oncology Practice

June 9th 2020

Andrew M. Evens, DO, MSc, discusses the telemedicine initiatives that have been taken at RCINJ—even before the COVID-19 outbreak—as well as proper telemedicine etiquette and best practices for oncologists getting a handle on the new approach in clinical practice.

Zanubrutinib Gains Approval in China for Relapsed/Refractory CLL/SLL and MCL

June 3rd 2020

China's National Medical Products Administration has approved zanubrutinib (Brukinsa) for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who have received at least 1 prior therapy, as well as for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.

Infigratinib Demonstrates Clinical Activity Across Settings in Urothelial Cancer

June 2nd 2020

Infigratinib was found to demonstrate clinical activity in patients with metastatic urothelial carcinoma, regardless of what line of therapy it was administered.

Darolutamide Improves OS, Delays Onset of Cancer-Related Morbidity and Subsequent Chemo in Nonmetastatic CRPC

May 31st 2020

Darolutamide (Nubeqa) plus androgen deprivation therapy led to a 31% reduction in the risk of death compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer.​​

Frontline Pembrolizumab/Axitinib Survival Benefit Upholds in Advanced RCC

May 31st 2020

The combination of pembrolizumab and axitinib continued to demonstrate a clinically significant improvement in progression-free and overall survival compared with sunitinib in patients with previously untreated, advanced renal cell carcinoma.

Pembrolizumab/Chemo Significantly Improves PFS in Frontline PD-L1-High TNBC

May 30th 2020

Pembrolizumab in combination with several chemotherapy partners led to a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy alone as a first-line treatment for patients with locally recurrent, inoperable, or metastatic triple-negative breast cancer whose tumors expressed PD-L1.

Adjuvant Osimertinib Significantly Improves DFS in Early-Stage EGFR+ NSCLC

May 29th 2020

Adjuvant treatment with osimertinib demonstrated an 83% reduction in the risk of disease recurrence or death in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer.

Orthopedic Oncologists Recommended for Consult on Bone Sarcoma Treatment After Osteointegration

May 26th 2020

R. Lor Randall, MD, FACS, discusses the cautions medical oncologists should take for their patients with bone sarcomas who undergo limb preservation with osteointegration, and the importance of keeping orthopedic oncologists in the loop.

LSZ102 Shows Encouraging Activity in Combination With Ribociclib, Alpelisib in ER+ Breast Cancer

May 26th 2020

LSZ102 was found to be well tolerated and demonstrate clinical activity in combination with either ribociclib or alpelisib in patients with estrogen receptor–positive breast cancer who have progressed on endocrine therapy.

NICE Recommends Atezolizumab Combo in Frontline TNBC

May 23rd 2020

The UK's National Institute for Health and Care Excellence has recommended the combination of atezolizumab and nab-paclitaxel as a treatment for patients with unresectable, locally advanced, or metastatic triple-negative breast cancer whose tumors express PD-L1 at a level of 1% or more and have not had prior chemotherapy for metastatic disease.

Entinostat/Exemestane Combo Misses OS Endpoint in HR+ Breast Cancer

May 23rd 2020

The combination of entinostat and exemestane did not show a statistically significant improvement in overall survival compared with exemestane alone in patients with advanced hormone receptor—positive, HER2-negative breast cancer who have progressed on a nonsteroidal aromatase inhibitor, missing the primary endpoint of the phase 3 E2112 trial.